|Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating …|
JR Bailey, AR Sedaghat, T Kieffer, T Brennan, PK Lee, M Wind-Rotolo, ...
Journal of virology 80 (13), 6441-6457, 2006
|Maintenance of viral suppression in HIV-1–infected HLA-B*57+ elite suppressors despite CTL escape mutations|
JR Bailey, TM Williams, RF Siliciano, JN Blankson
The Journal of experimental medicine 203 (5), 1357-1369, 2006
|Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors|
JN Blankson, JR Bailey, S Thayil, HC Yang, K Lassen, J Lai, SK Gandhi, ...
Journal of virology 81 (5), 2508-2518, 2007
|Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells|
KG Lassen, KX Ramyar, JR Bailey, Y Zhou, RF Siliciano
PLoS Pathog 2 (7), e68, 2006
|Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly …|
JR Bailey, KG Lassen, HC Yang, TC Quinn, SC Ray, JN Blankson, ...
Journal of virology 80 (10), 4758-4770, 2006
|Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses|
WO Osburn, AE Snider, BL Wells, R Latanich, JR Bailey, DL Thomas, ...
Hepatology 59 (6), 2140-2151, 2014
|Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo|
KG Lassen, JR Bailey, RF Siliciano
Journal of virology 78 (17), 9105-9114, 2004
|Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance|
SA Rabi, GM Laird, CM Durand, S Laskey, L Shan, JR Bailey, S Chioma, ...
The Journal of clinical investigation 123 (9), 3848-3860, 2013
|Elucidating the elite: mechanisms of control in HIV-1 infection|
KA O’Connell, JR Bailey, JN Blankson
Trends in pharmacological sciences 30 (12), 631-637, 2009
|Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor|
JR Bailey, K O'Connell, HC Yang, Y Han, J Xu, B Jilek, TM Williams, ...
Journal of virology 82 (15), 7395-7410, 2008
|Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus|
KA O'Connell, TP Brennan, JR Bailey, SC Ray, RF Siliciano, JN Blankson
Journal of virology 84 (14), 7018-7028, 2010
|Elite suppressor–derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics|
KG Lassen, MA Lobritz, JR Bailey, S Johnston, S Nguyen, B Lee, T Chou, ...
PLoS Pathog 5 (4), e1000377, 2009
|Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors|
SK Gandhi, JD Siliciano, JR Bailey, RF Siliciano, JN Blankson
Journal of virology 82 (6), 3125-3130, 2008
|Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs|
J Bailey, JN Blankson, M Wind-Rotolo, RF Siliciano
Current opinion in immunology 16 (4), 470-476, 2004
|Approaches, progress, and challenges to hepatitis C vaccine development|
JR Bailey, E Barnes, AL Cox
Gastroenterology 156 (2), 418-430, 2019
|Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance|
JR Bailey, AI Flyak, VJ Cohen, H Li, LN Wasilewski, AE Snider, S Wang, ...
JCI insight 2 (9), 2017
|Evolution of HIV-1 in an HLA-B* 57-positive patient during virologic escape|
JR Bailey, H Zhang, BW Wegweiser, HC Yang, L Herrera, A Ahonkhai, ...
The Journal of infectious diseases 196 (1), 50-55, 2007
|Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B* 57+ elite suppressors|
JR Bailey, TP Brennan, KA O'Connell, RF Siliciano, JN Blankson
Journal of virology 83 (1), 88-97, 2009
|Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance|
JR Bailey, LN Wasilewski, AE Snider, R El-Diwany, WO Osburn, Z Keck, ...
The Journal of clinical investigation 125 (1), 437-447, 2015
|HCV broadly neutralizing antibodies use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design|
AI Flyak, S Ruiz, MD Colbert, T Luong, JE Crowe Jr, JR Bailey, ...
Cell host & microbe 24 (5), 703-716. e3, 2018